MOLOGEN AG Jefferies 2014 London Healthcare Conference

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "MOLOGEN AG Jefferies 2014 London Healthcare Conference"

Transcription

1 Jefferies 2014 London Healthcare Conference London 20 November 2014

2 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this presentation regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forwardlooking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication. V

3 Agenda Business overview MGN1703 cancer immune therapy MGN1601 therapeutic vaccination against cancer EnanDIM - new generation of immunomodulators Key financials and summary

4 Company overview Biotechnology company pioneering in cancer immuno-therapies and DNA vaccines Two unique proprietary lead products MGN1703 DNA immunomodulator MGN1601 therapeutic vaccination Solid financing and cash inflow from capital increase in February

5 MOLOGEN: Pioneering cancer immune therapies MGN1703 MGN1601 Immunomodulator and TLR-9 agonist Colorectal cancer (mcrc) Small Cell Lung Cancer (SCLC) Therapeutic cancer vaccination Renal cancer Other solid tumors Other solid tumors Proof of efficacy (mcrc) Superior safety and tolerability Currently, two trials ongoing: 1. IMPALA: pivotal Phase III in mcrc ASET: Successful study phase I/II completed Superior safety and tolerability Promising overall survival data 2. IMPULSE randomized in SCLC

6 Agenda Business overview MGN1703 cancer immune therapy MGN1601 therapeutic vaccination against cancer EnanDIM - new generation of immunomodulators Key financials and summary

7 MGN1703 Cancer immunotherapies: New megatrend Science Magazine: Breakthrough of the Year 2013 Cancer immunotherapy is the use of the immune system or components of it to treat cancer

8 MGN1703 MGN1703: Best in Class TLR-9 Agonist No open ends - protection against degradation Only natural DNA components No chemical modifications High stability Broad activation of the immune system Only minimal side effects No dose-limiting toxicity High dosing over long periods of time Light blue area : recognized by TLR-9 receptor

9 MGN1703 Activate the immune system to fight cancer pdc plasmacytoid dendritic cell mdc myeloid dendritic cell NK cell natural killer cell NKT cell natural killer T cell

10 MGN1703 IMPACT phase II study in colorectal cancer: Outstanding long-term responses Primary endpoint met: Progression Free Survival (Hazard ratio: 0.55; p=0.04) Follow-up of four patients who continued MGN1703 treatment in compassionate use programs since no relapse at end of study: Three patients progression free in excess of months as of April 2014 Excellent safety and tolerability, also when treated long-term Secondary endpoint overall survival : results are not yet mature Predictive biomarkers identified: CEA level, tumor reduction by induction therapy, activated NKTs Findings from subgroup analyses used to optimize the IMPALA study design CEA carcinoembryonic antigen - a tumor marker for colorectal cancer NKT Natural Killer T cells

11 MGN1703 IMPALA: Pivotal study started in September 2014 Standard first-line chemotherapy for mcrc Trial Treatment Period Maintenance Re-Induction Induction CT weeks PR/CR Responder Screening/ Randomization 1:1 MGN1703 PD MGN1703 with induction CT PD Start of 2 nd line Control group PD Induction CT PD Primary endpoint: OS Secondary endpoints: e.g. progression-free survival, QoL, toxicity and safety Open-label, randomized controlled two-arm, multinational phase III trial 540 patients with metastatic colorectal cancer in more than 100 sites in eight European countries, including Top 5 European pharma markets mcrc metastatic colorectal cancer CT chemotherapy PR partial response CR complete response PD progressive disease OS overall survival QoL quality of life

12 MGN1703 IMPULSE study started in March 2014 Standard first-line chemotherapy for Extensive Disease SCLC Trial Treatment Period Maintenance Induction CT 4 cycles of platinum-based therapy PR/CR Responder Screening/ Randomization 3:2 Experimental arm: 5th cycle of platinum based CT followed by MGN1703 maintenance PD Start of 2 nd line Control group: 5th cycle of platinum based CT followed by local practice PD Primary endpoint: OS Secondary endpoint: progression-free survival Randomized controlled two-arm, multinational trial with 100 patients with extensive disease small cell lung cancer in Belgium, Austria, Germany and Spain Biomarkers are used as stratification factors: NSE levels and NKTs SCLC small cell lung cancer NSE neuron specific enolase - a tumor marker for lung cancer NKT Natural Killer T cells CT chemotherapy PR partial response CR complete response OS overall survival PD progressive disease

13 MGN1703 MGN1703: Successful safety trial in the U.S. Placebo-controlled, double-blind phase I study in healthy volunteers Favorable safety, tolerability and pharmacokinetic profile Consistent immune activation Investigational New Drug (IND) application approved by FDA for MGN1703 in solid tumors IND enables inclusion of the U.S. in the future MGN1703 development program FDA US Food and Drug Administration

14 MGN1703 MGN1703 Milestones Metastatic Colorectal Cancer (mcrc) IMPALA (Phase III trial) First patient in, PEP: OS IMPACT (Phase II trial) OS data expected IMPALA Recruitment completed IMPALA Primary analyses (OS), Filing/Approval / 2018 IMPULSE (randomized, controlled trial) First patient in, PEP: OS IMPULSE Recruitment completed IMPULSE Primary analyses (OS) Small Cell Lung Cancer (SCLC) PEP primary endpoint OS overall survival

15 Agenda Business overview MGN1703 cancer immune therapy MGN1601 therapeutic vaccination against cancer EnanDIM - new generation of immunomodulators Key financials and summary

16 MGN1601 Therapeutic vaccination against cancer MGN1601 Orphan Drug Status in EU

17 MGN1601 ASET: Promising data from renal cancer trial with tumor vaccine MGN1601 Final data set from ASET phase I/II study presented at scientific conferences in H1 2014: Primary endpoint met: Favorable safety and tolerability profile Promising overall survival data in subgroup of patients Identification of potential biomarkers Orphan Drug designation from EMA EMA European Medicines Agency

18 Agenda Business overview MGN1703 cancer immune therapy MGN1601 therapeutic vaccination against cancer EnanDIM - new generation of immunomodulators Key financials and summary

19 EnanDIM EnanDIM: New generation of immunomodulators Combining advantages of two types of TLR-9 agonists Broad immune activation shown in pre-clinical trials Potential application in the fields of cancer and anti-infective therapies MGN1703 Linear DNA-structure Closed, dumbbell-shaped structure Only natural DNA components Good safety and tolerability profile One additional production step Linear molecules Easy and cost-effective production Chemically modified structure ( ) EnanDIM =Enantiomeric DNA-based ImmunoModulator Linear molecules No chemical modifications Good safety and tolerability profile expected Easy and cost-effective production DNA sequence essential for function (so-called CG motifs ) New structural feature Protection against degradation

20 Agenda Business overview MGN1703 cancer immune therapy MGN1601 therapeutic vaccination against cancer EnanDIM - new generation of immunomodulators Key financials and summary

21 Key financials 9M 2014: Strong cash inflow from capital increase [in million] Sep Dec Cash & cash equiv % Balance sheet total % Balance sheet dominated by cash inflow from capital increase of around 16m Equity ratio 86% 94% -9% [in million] 9M M 2013 R&D expenses % EBIT % Cash flow from operating activities % Cash flow from financing activities % Monthly cash burn % Preparation of IMPALA and start of IMPULSE studies main drivers of increased R&D costs Monthly cash burn increased accordingly CF from financing activities includes capital increase

22 Lead products: Unique profile and huge market potential MGN1703 MGN1601 First-line maintenance Long-term treatment Usable for various indications Blockbuster Potential Superior safety and tolerability Suitable for mono- and combination therapy Patient selection via biomarker

23 Corporate calendar and contact details March 25, 2015 Financial Year 2014 May 12, 2015 Quarterly Report as of March 31, 2015 August 13, 2015 Quarterly Report as of June 30, 2015 November 12, 2015 Quarterly Report as of September 30, 2015 Claudia Nickolaus Head of IR & Communications Phone: Fax: MOLOGEN, MIDGE, dslim, and EnanDIM are registered trademarks of the 22

24 APPENDIX

25 Advanced product pipeline with strong focus on cancer immune therapies Pre-clinic Phase I Phase II Phase III/ Approval EnanDIM Oncology & Anti-infectives MGN Other solid tumors MGN Small cell lung cancer MGN Colorectal cancer MGN1331 Leishmaniasis MGN1601 Renal cancer MGN1333 Hepatitis B MGN Malignant melanoma Oncology Infectious diseases Oncology & Infectious diseases 1 IND (Investigational New Drug) filed in U.S.; safety trial in U.S. completed 2 Collaboration with Max-Delbrueck-Center for Molecular Medicine and Charité Universitaetsmedizin, Berlin

26 IMPACT study design Induction CT months Trial Treatment Period Maintenance mcrc patients treated first-line with FOLFOX/ XELOX or FOLFIRI +/- Bevacizumab* * at investigators discretion At least SD Screening/ Randomization 1:1 Experimental arm: 60mg MGN1703 twice weekly s.c. No maintenance Placebo twice weekly s.c. PD ** PD ** ** Treatment after PD at investigators discretion Primary endpoint met: PFS Secondary endpoint: OS Double-blind, randomized, placebo-controlled, two-arm, multinational phase II trial in 59 patients with mcrc from six European countries Predictive biomarkers identified: CEA level, tumor reduction by induction therapy, activated NKTs Start: June 2010 primary completion date: February 2013 CT chemotherapy SD stable disease PD progressive disease s.c. subcutaneous injection OS overall survival CEA carcinoembryonic antigen - a tumor marker for colorectal cancer NKT Natural Killer T cells mcrc metastatic colorectal cancer PFS progression free survival

27 ASET study design Trial Treatment Period Treatment per protocol (TPP) Extension phase Patients with advanced renal cell cancer No standard therapy available Trial inclusion 8 applications of MGN1601 in 12 weeks i.d. Disease Control Max. 5 applications in week 24, 36, 48, 72, and 120 PD** PD** ** Treatment after PD at investigators discretion Primary endpoints met: safety and tolerability Open-label, proof-of-principle, multi-center phase I/II trial 19 patients with advanced renal cell carcinoma who failed prior systemic therapies Orphan drug designation from EMA Start: December 2010 primary completion date: August 2013 PD progressive disease i.d. intradermal injection EMA European Medicines Agency

28 MOLOGEN shares ISIN DE Shares issued: 16,973,626 Max. 1.6 million share options (employee stock option plans) Frankfurt Stock Exchange (Prime Standard): MGN Reuters: MGNG.DE Distribution of shares (estimates) Free float 53% Private investor, Germany 24% Deutscher Ring Krankenversicherungsverein a.g., Germany 8% Baloise Holding, Switzerland 8% Salvator Vermoegensverwaltungs GmbH, Germany 7%

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

MOLOGEN AG. Dr. Matthias Schroff Chief Executive Officer Dr. Alfredo Zurlo Chief Medical Officer. Roadshow Abu Dhabi, Dubai April 2015

MOLOGEN AG. Dr. Matthias Schroff Chief Executive Officer Dr. Alfredo Zurlo Chief Medical Officer. Roadshow Abu Dhabi, Dubai April 2015 Dr. Matthias Schroff Chief Executive Officer Dr. Alfredo Zurlo Chief Medical Officer Roadshow Abu Dhabi, Dubai April 2015 Disclaimer Certain statements in this presentation contain formulations or terms

More information

MOLOGEN AG German Equity Forum 2015

MOLOGEN AG German Equity Forum 2015 German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies

More information

COMPANY PRESENTATION JUNE 2016

COMPANY PRESENTATION JUNE 2016 COMPANY PRESENTATION JUNE 2016 Agenda Business Overview and Next Level Strategy Market TLR9 Agonist Product Family: Lefitolimod (MGN1703) EnanDIM New Generation of Immunomodulators MGN1601 Therapeutic

More information

STRATEGY PROGRAM NEXT LEVEL BERLIN, 9 JUNE 2016

STRATEGY PROGRAM NEXT LEVEL BERLIN, 9 JUNE 2016 STRATEGY PROGRAM NEXT LEVEL BERLIN, 9 JUNE 2016 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments, as well as negations of

More information

MOLOGEN AG interim report as of March 31, 2015 Key data 2

MOLOGEN AG interim report as of March 31, 2015 Key data 2 Interim report as of March 31, 2015 MOLOGEN AG interim report as of March 31, 2015 Key data 2 Highlights Slight decline in research and development expenses EBIT improved accordingly Ongoing recruitment

More information

MOLOGEN AG interim report as of September 30, 2015 Key data 2. Patient recruitment for lung cancer and HIV studies successfully completed

MOLOGEN AG interim report as of September 30, 2015 Key data 2. Patient recruitment for lung cancer and HIV studies successfully completed Interim report as of September 30, MOLOGEN AG interim report as of September 30, Key data 2 Highlights Patient recruitment for lung cancer and HIV studies successfully completed At 10.4 million, R&D expenses

More information

MOLOGEN AG interim report as of June 30, 2015 Key data 2. H1 2015 H1 2014 Change % Revenues 0 0 0 0 0 0 Profit (loss) from operations (EBIT)

MOLOGEN AG interim report as of June 30, 2015 Key data 2. H1 2015 H1 2014 Change % Revenues 0 0 0 0 0 0 Profit (loss) from operations (EBIT) Interim report as of June 30, 2015 MOLOGEN AG interim report as of June 30, 2015 Key data 2 Highlights Slight decline in research and development expenses EBIT improved accordingly Ongoing recruitment

More information

THE POWER OF IMMUNOTHERAPIES THE POWER OF IMMUNO- THERAPIES

THE POWER OF IMMUNOTHERAPIES THE POWER OF IMMUNO- THERAPIES THE POWER OF IMMUNOTHERAPIES THE POWER OF IMMUNO- THERAPIES ANNUAL REPORT 2015 MOLOGEN ANNUAL REPORT 2015 HIGHLIGHTS / KEY DATA HIGHLIGHTS END IN SIGHT We have reached important milestones for clinical

More information

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous

More information

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

MOLOGEN. Our research - for you. Interim Report as of March 31, 2013

MOLOGEN. Our research - for you. Interim Report as of March 31, 2013 MOLOGEN. Our research - for you Interim Report as of March 31, 2013 MOLOGEN AG interim report as of March 31, 2013 Key data 2 KEY DATA of MOLOGEN AG according to IFRS as of March 31, 2013 Statement of

More information

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information

MOLOGEN: Our research for you. Interim financial statements as of June 30, 2011

MOLOGEN: Our research for you. Interim financial statements as of June 30, 2011 MOLOGEN: Our research for you Interim financial statements as of June 30, 2011 2 Key figures MOLOGEN AG Interim financial statements as of June 30, 2011 KEY FIGURES of MOLOGEN AG for the first half of

More information

Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014

Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014 Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology November 17, 2014 Forward-looking statements Our discussions during this conference call will

More information

Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO

Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO 1 PCI BIOTECH Important notice and disclaimer This presentation may contain certain forward-looking statements and forecasts based

More information

Foundational Issues Related to Immunotherapy and Melanoma

Foundational Issues Related to Immunotherapy and Melanoma Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Corporate Presentation June 2, 2015

Corporate Presentation June 2, 2015 Corporate Presentation June 2, 2015 SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these

More information

Aeterna Zentaris. 11 th Annual Needham Healthcare Conference April 3, 2012. Committed to cure

Aeterna Zentaris. 11 th Annual Needham Healthcare Conference April 3, 2012. Committed to cure 11 th Annual Needham Healthcare Conference April 3, 2012 Forward-Looking Statements This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities

More information

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

More information

Endpoint Selection in Phase II Oncology trials

Endpoint Selection in Phase II Oncology trials Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill aivanova@bios.unc.edu Primary endpoints in Phase II trials Recently looked at journal articles

More information

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation

Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Hans S. Keirstead President, NeoStem Oncology NeoStem Presented by GTC, a conference production company 626-256-6405

More information

Detecting Cancer in Blood. Company presentation

Detecting Cancer in Blood. Company presentation Detecting Cancer in Blood Company presentation Safe harbor statement Forward Looking Statements This communication contains certain forward-looking statements, including, without limitation, statements

More information

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO ENCORE 601 Phase 1b dose escalation has been completed and safety confirmation has commenced

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

Immunovaccine Inc. (TSX-V: IMV) July 2011

Immunovaccine Inc. (TSX-V: IMV) July 2011 Immunovaccine Inc. (TSX-V: IMV) July 2011 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities

More information

A Study To Evaluate PF With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Study To Evaluate PF With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome A service of the U.S. National Institutes of Health Trial record 1 of 5 for: efficacy of PF-04449913 Previous Study Return to List Next Study A Study To Evaluate PF-04449913 With Chemotherapy In Patients

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED

BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination

More information

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,

More information

CAN-FITE BIOPHARMA LTD.

CAN-FITE BIOPHARMA LTD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month

More information

Niraparib (PARP Inhibitor) Phase 3 Pivotal Program for Ovarian Cancer February 14, 2013

Niraparib (PARP Inhibitor) Phase 3 Pivotal Program for Ovarian Cancer February 14, 2013 Niraparib (PARP Inhibitor) Phase 3 Pivotal Program for Ovarian Cancer February 14, 2013 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical

More information

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from

More information

Overview of Drug Development

Overview of Drug Development Overview of Drug Development Namrata Bahadur Head of Clinical Development & Medical Affairs Emerging Growth Markets 17 th 21 st March, Bangkok 2008 Novartis The information within this presentation is

More information

The Clinical Trial Protocol Guide. BioStrategics Consulting Ltd.

The Clinical Trial Protocol Guide. BioStrategics Consulting Ltd. The Clinical Trial Protocol Guide 2011 BioStrategics Consulting Ltd. BioStrategics Consulting Ltd THE CLINICAL TRIAL PROTOCOL The clinical trial protocol to test one s product, to confirm or reject a specific

More information

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase

More information

Understanding Clinical Trials

Understanding Clinical Trials Understanding Clinical Trials HR =.6 (CI :.51.7) p

More information

The Ultimate Healthcare & Biotechnology Event in 2010. Deborah Rathjen CEO & Managing Director 24 March 2010

The Ultimate Healthcare & Biotechnology Event in 2010. Deborah Rathjen CEO & Managing Director 24 March 2010 The Ultimate Healthcare & Biotechnology Event in 2010 Deborah Rathjen CEO & Managing Director 24 March 2010 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking"

More information

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment

Localised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The

More information

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

9. WestLB Deutschland Conference. Frankfurt November 16, 2011

9. WestLB Deutschland Conference. Frankfurt November 16, 2011 9. WestLB Deutschland Conference Frankfurt November 16, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282

IMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris

More information

Eigenkapitalforum 2013. Company Update November 12, 2013

Eigenkapitalforum 2013. Company Update November 12, 2013 Eigenkapitalforum 2013 Company Update November 12, 2013 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

Drug/Drug Combination: Bevacizumab in combination with chemotherapy

Drug/Drug Combination: Bevacizumab in combination with chemotherapy AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy

More information

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Come è cambiata la storia naturale della malattia

Come è cambiata la storia naturale della malattia Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal

More information

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for

More information

Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development

Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development Strasbourg, 11 March 2008 Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development Strasbourg, France, March 11, 2008 Transgene (Euronext Paris: FR0005175080) announces

More information

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of

More information

Additional 50 patients enrolled in KEYNOTE-001 with analyses planned using Merck s proprietary PD-L1 assay at one percent and 50 percent cut points

Additional 50 patients enrolled in KEYNOTE-001 with analyses planned using Merck s proprietary PD-L1 assay at one percent and 50 percent cut points News Release Media Contacts: Annick Robinson Dominique Quirion Merck NATIONAL Annick.robinson@merck.com dquirion@national.ca 514 428-2890 514 843-2302 Investor Contacts: Justin Holko: (+1 908-423-5088

More information

Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland

Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland Swiss-Scandinavian Bio-Business Seminar, 10 February 2016 Zurich, Switzerland Tone Kvåle, Chief Financial Officer Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway - www.nordicnanovector.com

More information

OCT Practical Aspects of Conducting Clinical Trials for Russian Innovative Companies

OCT Practical Aspects of Conducting Clinical Trials for Russian Innovative Companies OCT Practical Aspects of Conducting Clinical Trials for Russian Innovative Companies Innovative Drug Research and Development in Russia 2012 OCT: CRO in Russia, Central and Eastern Europe Russian Innovative

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

News Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma

News Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Markus Talanow +49 6151 72 7144 Investor Relations +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor

More information

The Promise and Challenge of Adaptive Design in Oncology Trials

The Promise and Challenge of Adaptive Design in Oncology Trials THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic

More information

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.

More information

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research

More information

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

More information

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

More information

levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (395/07) UCB Pharma Limited

levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (395/07) UCB Pharma Limited Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (395/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro

Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro PRESS RELEASE Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro BioChaperone Lispro is significantly faster than Humalog in type I diabetic patients;

More information

NCT Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety,

NCT Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety, NCT02020291 Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients with Metastatic Breast, Colon or Prostate

More information

Oxford BioMedica. Annual Results 2008

Oxford BioMedica. Annual Results 2008 Oxford BioMedica Annual Results 2008 12 March 2009 Disclaimer This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the Securities ). Although reasonable

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - Adaptimmune Reports Full Fiscal Year 2015 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA, Pa. and OXFORD, United Kingdom., October 13, 2015 Adaptimmune

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin

More information

Clinical Trials: The Crux of Cancer Innovation

Clinical Trials: The Crux of Cancer Innovation Clinical Trials: The Crux of Cancer Innovation Even as medical science is transforming cancer care, major deficiencies in the way cancer clinical trials are designed, carried out, regulated and funded

More information

Deutsches Eigenkapitalforum. Frankfurt November 22, 2011

Deutsches Eigenkapitalforum. Frankfurt November 22, 2011 Deutsches Eigenkapitalforum Frankfurt November 22, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd.

Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Acquisition of Boston Biomedical Inc. February 29, 2012 Dainippon Sumitomo Pharma Co., Ltd. Oncology Strategy and Acquisition Significance 1 Commitment to Oncology Entering the Oncology Area Globally External

More information

Kempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011

Kempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011 Kempen & Co 4 th Healthcare/Life Sciences Conference Brussels March 29, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

What You Need to Know About Lung Cancer Immunotherapy

What You Need to Know About Lung Cancer Immunotherapy What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer

More information

Newsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective:

Newsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective: Newsletter This resume of the results from the phase 1 study with Foxy-5 is based on clinical and laboratory data from the study, and these data have now been locked into the database. The full report

More information

Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer

Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer Primary safety and feasibility endpoints achieved Preliminary positive signs of antitumoral effect in all evaluable

More information

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/

More information

Nuevas tecnologías basadas en biomarcadores para oncología

Nuevas tecnologías basadas en biomarcadores para oncología Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS

More information

Clinical Trials Register

Clinical Trials Register Page 1 of 10 EU-CTR Version: 1.1.1 EU Clinical Trials Register Search for Clinical Trials Home Search About Glossary Data Quality Joining a trial Contacts EudraPharm Clinicaltrialsregister.eu Summary EudraCT

More information

Santhera Reports Successful 2006

Santhera Reports Successful 2006 Published: 07:00 02.03.2007 GMT+1 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649 Santhera Reports Successful 2006 Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty

More information

Recruiting now. Could you help by joining this study?

Recruiting now. Could you help by joining this study? Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate

More information

10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio

10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio 10 th EADO Congress Vilnius, 7-10 May 2014 Ipilimumab update Michele Maio Medical Oncology and Immunotherapy, Department of Oncology University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY Evolving

More information

Commerzbank Sector Conference. Frankfurt August 30, 2011

Commerzbank Sector Conference. Frankfurt August 30, 2011 Commerzbank Sector Conference Frankfurt August 30, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking

More information

CORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER 2016

CORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER 2016 CORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER 2016 Financial results in line with plan Cash and cash equivalents of EUR 25.5 million; cash reach until the end

More information

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this

More information

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate + Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN

More information

BNC105 PHASE II RENAL CANCER TRIAL RESULTS

BNC105 PHASE II RENAL CANCER TRIAL RESULTS ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient

More information

Navigating GIST. The Life Raft Group June 12, 2008

Navigating GIST. The Life Raft Group June 12, 2008 Navigating GIST Clinical Trials The Life Raft Group June 12, 2008 Some observations: Annually, only 3% of adult patients participate in cancer clinical trials. Lara et. al; Evaluation of factors affecting

More information

Company update. German Equity Forum, Frankfurt November 2011

Company update. German Equity Forum, Frankfurt November 2011 Company update German Equity Forum, Frankfurt November 2011 At a glance Oncology-focused biopharmaceutical company Transition from R&D to commercially driven business Product candidates with strong competitive

More information

Company presentation. 7 th European Life Science CEO Forum Zurich, 4-5 March 2014. Paolo Bassanini Business Development & IR

Company presentation. 7 th European Life Science CEO Forum Zurich, 4-5 March 2014. Paolo Bassanini Business Development & IR Company presentation 7 th European Life Science CEO Forum Zurich, 4-5 March 2014 Paolo Bassanini Business Development & IR Forward-looking statements The presentation contains certain forward-looking statements.

More information

Clinical Trial Endpoints for Regulatory Approval First-Line Therapy for Advanced Ovarian Cancer

Clinical Trial Endpoints for Regulatory Approval First-Line Therapy for Advanced Ovarian Cancer Clinical Trial Endpoints for Regulatory Approval First-Line Therapy for Advanced Ovarian Cancer Elizabeth Eisenhauer MD FRCPC Options for Endpoints First-Line Trials in Advanced OVCA Overall Survival:

More information

Moving forward, where are we with Clinical Trials?

Moving forward, where are we with Clinical Trials? Moving forward, where are we with Clinical Trials? Dennis A. Wigle Division of Thoracic Surgery Mayo Clinic AATS/STS General Thoracic Surgery Symposium Sunday, April 27 th 2014 2012 MFMER slide-1 Where

More information

New Advances in Cancer Treatments. March 2015

New Advances in Cancer Treatments. March 2015 New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Groundbreaking Collaborative Clinical Trial Launched

Groundbreaking Collaborative Clinical Trial Launched Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)

More information

Q3 2015 Conference Call

Q3 2015 Conference Call November 4, 2015 Q3 2015 Conference Call 1 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements

More information